Objective: To review clinical data on direct oral anticoagulants (DOACs) used in the acute
treatment of venous thromboembolism (VTE) as well as practical considerations when using …

Abstract Background: Venous thromboembolism (VTE), comprising deep vein thrombosis
(DVT) and pulmonary embolism (PE), is a major cause of morbidity, mortality, and …

The treatment of acute venous thromboembolism (VTE) is being completely modified with
the development of direct oral anticoagulants (DOACs). Rivaroxaban, apixaban and …

Venous thromboembolism (VTE) is a major cause of morbidity, mortality, and healthcare
expenditure. In the United States, approximately 0.1% of the population experiences an …

Background Numerous new oral anticoagulants (NOACs) have been compared to a
parenteral anticoagulant/oral vitamin K antagonist (VKA) for the treatment of acute venous …

Venous thromboembolism (VTE) is a prevalent, potentially fatal health problem. Although
standard anticoagulant therapy is effective when compared with the newer direct oral …

Introduction: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in
the western world. The approval of non-vitamin K oral anticoagulants (NOACs) as …

The new oral anticoagulants (NOACs), which include dabigatran, rivaroxaban, apixaban,
and edoxaban, are poised to replace warfarin for treatment of the majority of patients with …

As a result of the successful completion of their respective phase III studies compared with
vitamin K antagonists (VKAs), four direct oral anticoagulants (DOACs) have been approved …

Venous thromboembolism (VTE) is a serious medical condition associated with significant
morbidity and mortality, and an incidence that is expected to double in the next forty years …